COVID-19, caused by the SARS-CoV-2 virus, has revealed a complex interplay between
inflammation and coagulation, leading to the emergence of the concept of thrombo …

Background: There was controversy surrounding the optimal thromboprophylaxis strategy
for coronavirus disease 2019 (COVID-19) patients. This included debates on the dosage of …

Based on emerging evidence from the COVID-19 pandemic, the International Society on
Thrombosis and Haemostasis (ISTH) guidelines for antithrombotic treatment in COVID-19 …

Abstract Coronavirus disease 2019 (COVID-19) carries a high risk of vascular thrombosis.
However, whether a specific anticoagulation intensity strategy may prevent clinical …

Thromboprophylaxis/anticoagulation treatment is often required in hospitalized COVID-19
patients. We aimed to estimate the prevalence of major bleeding events in hospitalized …

Imatinib, an ABL tyrosine-kinase inhibitor, shows promise in restoring endothelial barrier
function in patients with COVID-19, thus, preventing cytokine leakage from the alveolar …

We would like to thank the interest of Kow et al. in our study. In the letter, they expressed
their skepticism that therapeutic dose anticoagulation therapy can reduce mortality in …

Purpose To assess risk factors for arterial and venous thromboses (AVT) in patients
hospitalized in general wards for COVID-19 pneumonia and requiring oxygen therapy …

A systemic inflammatory response occurs during SARS-CoV2 infection and is associated
with hypercoagulability and thrombotic events. From March 2020 in our hospital different …

We are grateful to Dr Chia Sang Kow and colleagues 1 for their interest in our study 2
evaluating the cardiovascular morbidity–mortality at 3 months post-discharge from …